Effectiveness of a proprietary Dichrostachys glomerata extract (DYG-400®) on Adult's Sleep Quality and Activity: A Pilot Trial

Objectives: The purpose of this study was to examine the effectiveness of Dichrostachys glomerata (Dyglomera^®) supplementation on adults’ sleep quality and daytime activity.

Methods: Using a double-blind placebo-controlled pilot trial, 56 adults with nonclinical poor sleep (M age = 44.50) were randomized to either the Dichrostachys glomerata Group (300 mg/d) or Placebo Group for 60 days. Outcomes were the self-reported Insomnia Severity Index and objective sleep and daytime activity via the Oura Ring. Analysis was undertaken at Day 0 (Baseline), Day 30, and Day 60.

Results: The Dichrostachys glomerata Group had improved Insomnia Severity Index symptoms, with significant improvements from Day 0 to Day 60. Objective sleep measures indicated that the Dichrostachys glomerata Group had significantly improved sleep score and deep sleep duration, while the Placebo Group declined in these parameters. The Dichrostachys glomerata Group also improved on sleep latency and time awake, contrasting with worsened of these sleep metrics in the Placebo Group, p’s < .05. No group differences were found for REM. The Dichrostachys glomerata Group improved significantly on the activity outcomes.

Conclusion: These results provide preliminary support for the potential of Dichrostachys glomerata supplementation to enhance both sleep and daytime activity. Further research is warranted to validate these findings in diverse populations. Clinical trial registry = ISRCTN10099861.